Inovio Pharmaceuticals Stock Performance
| INO Stock | USD 1.61 0.08 5.23% |
The company retains a Market Volatility (i.e., Beta) of 0.31, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inovio Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Inovio Pharmaceuticals is expected to be smaller as well. At this point, Inovio Pharmaceuticals has a negative expected return of -0.58%. Please make sure to check out Inovio Pharmaceuticals' skewness, as well as the relationship between the day median price and relative strength index , to decide if Inovio Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Inovio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 14.3 M | |
| Total Cashflows From Investing Activities | 104.1 M |
Inovio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 250.00 in Inovio Pharmaceuticals on November 1, 2025 and sell it today you would lose (89.00) from holding Inovio Pharmaceuticals or give up 35.6% of portfolio value over 90 days. Inovio Pharmaceuticals is generating negative expected returns assuming volatility of 5.1748% on return distribution over 90 days investment horizon. In other words, 46% of stocks are less volatile than Inovio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Inovio Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Inovio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.61 | 90 days | 1.61 | about 84.13 |
Based on a normal probability distribution, the odds of Inovio Pharmaceuticals to move above the current price in 90 days from now is about 84.13 (This Inovio Pharmaceuticals probability density function shows the probability of Inovio Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon Inovio Pharmaceuticals has a beta of 0.31. This usually indicates as returns on the market go up, Inovio Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Inovio Pharmaceuticals will be expected to be much smaller as well. Additionally Inovio Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Inovio Pharmaceuticals Price Density |
| Price |
Predictive Modules for Inovio Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inovio Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inovio Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Inovio Pharmaceuticals is not an exception. The market had few large corrections towards the Inovio Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inovio Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inovio Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.6 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 0.30 | |
Ir | Information ratio | -0.12 |
Inovio Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inovio Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inovio Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals may become a speculative penny stock | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 M) with loss before taxes, overhead, and interest of (56.65 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (104.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. |
Inovio Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inovio Stock often depends not only on the future outlook of the current and potential Inovio Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inovio Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.2 M | |
| Cash And Short Term Investments | 94.1 M |
Inovio Pharmaceuticals Fundamentals Growth
Inovio Stock prices reflect investors' perceptions of the future prospects and financial health of Inovio Pharmaceuticals, and Inovio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inovio Stock performance.
| Return On Equity | -3.28 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (492.03) % | |||
| Current Valuation | 63.99 M | |||
| Shares Outstanding | 68.7 M | |||
| Price To Earning | (5.43) X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 606.64 X | |||
| Revenue | 217.76 K | |||
| EBITDA | (103.95 M) | |||
| Cash And Equivalents | 348.13 M | |||
| Cash Per Share | 1.40 X | |||
| Total Debt | 11.87 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | (0.14) X | |||
| Cash Flow From Operations | (104.08 M) | |||
| Earnings Per Share | (2.72) X | |||
| Total Asset | 113.2 M | |||
| Retained Earnings | (1.73 B) | |||
| Current Asset | 171.85 M | |||
| Current Liabilities | 31.47 M | |||
About Inovio Pharmaceuticals Performance
By examining Inovio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Inovio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Inovio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Inovio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 317 people.Things to note about Inovio Pharmaceuticals performance evaluation
Checking the ongoing alerts about Inovio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inovio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals may become a speculative penny stock | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 M) with loss before taxes, overhead, and interest of (56.65 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (104.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. |
- Analyzing Inovio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inovio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Inovio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inovio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inovio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inovio Pharmaceuticals' stock. These opinions can provide insight into Inovio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Stock sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value—what Inovio Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.